Marc Banjak, Chief Legal Officer at iBio, Inc. (IBIO), bought 26,434 shares at $1.64 ($44K) on 2026-03-26, disclosed to the SEC on 2026-03-27.
CLO Marc Banjak purchased $20,531 worth of stock at $1.64, marking the largest insider purchase in the company's history. This bullish bet comes as the stock has crashed 60% over the last year and insiders have recently increased their net buying flow.
The stock is currently trading at $1.76, down 15.79% over the past five days and down 60.09% over the last year. It is trading 62.87% below its 52-week high of $4.74.
Catalysts include the initiation of the Phase 1 trial for IBIO-600 in Australia on April 24, 2026, and the upcoming Q2 earnings report mentioned in February 2026. Additionally, a cluster of two other insider purchases in the last 30 days suggests growing conviction among management.
The stock carries significant risk with a short interest of 9.52% of the float, and the company missed earnings estimates by -57.14% in Q1 2025.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.64 | 12,500 | $21K | 47.1% |
| 2 | $1.64 | 12,500 | $21K | 47.1% |
| 3 | $1.76 | 1,434 | $3K | 5.8% |
| Total | $1.65 avg | 26,434 | $44K | 100% |